Overall rank by patents
#47,617
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView US Corporation
Imstem Biotechnology, Inc.
USPTO PatentsView assignee record - 5 granted patents across 3 technology areas, active 2017–2020. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA).
5
Total patents granted
3
CPC technology areas
12.2
Avg claims per patent
-33%
5-year filing velocity
The verdict
Imstem holds 5 US patents across 3 technology areas, rank #47,617 of 50,000 tracked assignees.
- #47,617
- of 50,000 US assignees by volume
- Top 94%
- by Innovation Score (19.6/100)
- 12.2
- avg claims per patent
- -33%
- filing velocity, last 5 yrs
Portfolio overview
Imstem Biotechnology, Inc. has been granted 5 US utility patents between 2017 and 2020, placing Imstem Biotechnology, Inc. at rank #47,617 across all assignees tracked by PlainPatent. This portfolio spans 3 distinct Cooperative Patent Classification (CPC) subclasses, averaging 12.2 claims per patent with primary concentration in C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA). As a US Corporation, Imstem Biotechnology, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Imstem sits between Immunicom Inc. (5 patents, rank #47,613) and Indevr, Inc. (5 patents, rank #47,621) - the closest US assignees by grant volume. The composite Innovation Score of 19.6/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 2 grants, compared with 3 in the 2015–2019 window, a -33% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Imstem Biotechnology, Inc.'s 12.2 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while specialization in 3 subclasses reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Imstem Biotechnology, Inc. against peers pursuing similar technology classes.
Who files at Imstem's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Immunicom
IMMUNICOM INC.
5 patents
- Impact
IMPACT TECHNOLOGIES, LLC
5 patents
- Impacto Protectiv…
IMPACTO PROTECTIVE PRODUCTS INC.
5 patents
- Impetus
IMPETUS TECHNOLOGIES, INC.
5 patents
- Inail—Istituto Na…
INAIL—ISTITUTO NAZIONALE PER L'ASSICURAZIONE CONTRO GLI INFORTUNI SUL LAVORO
5 patents
- Inauth
INAUTH, INC.
5 patents
- Incozen Therapeut…
INCOZEN THERAPEUTICS PVT. LTD.
5 patents
- Indevr
INDEVR, INC.
5 patents
- Imstem Biotechnol… ◀
IMSTEM BIOTECHNOLOGY, INC.
5 patents
What this shows Imstem holds 5 patents at rank #47,617, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Imstem
By rank, the assignees closest to #47,617 in granted patent volume.
- Immunicom Inc. #47,613 · 5 patents
- Impact Technologies, Llc #47,614 · 5 patents
- Impacto Protective Products Inc. #47,615 · 5 patents
- Impetus Technologies, Inc. #47,616 · 5 patents
- Inail—istituto Nazionale PER L'assicurazione Contro GLI Infortuni SUL Lavoro #47,618 · 5 patents
- Inauth, Inc. #47,619 · 5 patents
- Incozen Therapeutics PVT. Ltd. #47,620 · 5 patents
- Indevr, Inc. #47,621 · 5 patents
Leaders in C12N (Microorganisms OR Enzymes)
Other assignees with the most granted patents in Imstem's primary technology class.
- Monsanto Technology Llc 1,335 in class
- The Regents Of The University Of California 1,161 in class
- Novozymes A/s 656 in class
- Immatics Biotechnologies Gmbh 647 in class
- Pioneer Hi-bred International, Inc. 623 in class
- President And Fellows Of Harvard College 594 in class
- Massachusetts Institute Of Technology 541 in class
- The Trustees Of The University Of Pennsylvania 537 in class
Imstem's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
20 Top 94% higher than 6% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2017 | 2 | 40.0% |
| 2019 | 1 | 20.0% |
| 2020 | 2 | 40.0% |
Which technologies does Imstem Biotechnology, Inc. patent most?
Top 3 of 3 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Specialized
Claim Depth Standard
Velocity Declining
Frequently Asked Questions
How many patents does Imstem Biotechnology, Inc. hold?
Imstem Biotechnology, Inc. holds 5 US granted patents filed between 2017 and 2020, spanning 3 technology areas.
What is Imstem Biotechnology, Inc.'s Innovation Score?
Imstem Biotechnology, Inc. has an Innovation Score of 19.6 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Imstem Biotechnology, Inc. focus on?
Imstem Biotechnology, Inc.'s top technology area is C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA) with 5 patents. The company has filed patents in 3 CPC subclasses total.
Is Imstem Biotechnology, Inc.'s patent filing rate increasing or decreasing?
Imstem Biotechnology, Inc.'s recent filing velocity is -33% compared to the prior five-year period. Filing activity has slowed relative to earlier years.
What does claim depth mean for Imstem Biotechnology, Inc.'s patents?
Imstem Biotechnology, Inc.'s patents average 12.2 claims each. This falls within the standard range, providing solid legal coverage.
How is the Imstem Biotechnology, Inc. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
Imstem's 5 grants land it in the top 94% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Imstem ranks #47,617 of 50,000. Top 50 holders
- Most of this portfolio concentrates in C12N - see who else leads that technology area. C12N leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.